Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $25.44 Consensus PT from Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned an average rating of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $24.25.

Several brokerages have recently issued reports on ARCT. B. Riley Financial initiated coverage on Arcturus Therapeutics in a report on Wednesday, March 18th. They set a “buy” rating and a $22.00 price target for the company. Weiss Ratings upgraded Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, April 21st. Finally, Citigroup cut their price objective on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $7.28 on Friday. Arcturus Therapeutics has a twelve month low of $5.85 and a twelve month high of $24.17. The firm has a market cap of $206.90 million, a PE ratio of -2.59 and a beta of 2.37. The firm’s 50 day moving average price is $7.63 and its two-hundred day moving average price is $7.45.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%.The firm had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $6.30 million. Equities analysts anticipate that Arcturus Therapeutics will post -3.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ARCT. Osaic Holdings Inc. raised its stake in shares of Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 738 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,567 shares in the last quarter. Bank of America Corp DE boosted its stake in Arcturus Therapeutics by 0.7% during the second quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock worth $3,805,000 after buying an additional 2,098 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 2,586 shares during the period. Finally, Two Sigma Investments LP increased its holdings in Arcturus Therapeutics by 3.3% in the 3rd quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock valued at $1,644,000 after buying an additional 2,857 shares during the period. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.